These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34328594)

  • 21. Initiation and propagation of α-synuclein aggregation in the nervous system.
    Hijaz BA; Volpicelli-Daley LA
    Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
    Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
    J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid rafts and human diseases: why we need to target gangliosides.
    Fantini J
    FEBS Open Bio; 2023 Sep; 13(9):1636-1650. PubMed ID: 37052878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between Parkin and
    Madsen DA; Schmidt SI; Blaabjerg M; Meyer M
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-translational modification of α-synuclein in Parkinson's disease.
    Barrett PJ; Timothy Greenamyre J
    Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease.
    Feng ST; Wang ZZ; Yuan YH; Sun HM; Chen NH; Zhang Y
    Eur J Neurosci; 2021 May; 53(9):2946-2959. PubMed ID: 32031280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
    Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
    Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
    Pozo Devoto VM; Falzone TL
    Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is a cure for Parkinson's disease hiding inside us?
    Santos J; Pallarès I; Ventura S
    Trends Biochem Sci; 2022 Aug; 47(8):641-644. PubMed ID: 35193796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.
    Galvagnion C
    J Parkinsons Dis; 2017; 7(3):433-450. PubMed ID: 28671142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.
    Grassi D; Howard S; Zhou M; Diaz-Perez N; Urban NT; Guerrero-Given D; Kamasawa N; Volpicelli-Daley LA; LoGrasso P; Lasmézas CI
    Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2634-E2643. PubMed ID: 29487216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD.
    Chang C; Lang H; Geng N; Wang J; Li N; Wang X
    Neurosci Lett; 2013 Aug; 548():190-5. PubMed ID: 23792198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.
    Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S
    Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
    Atsmon-Raz Y; Miller Y
    ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
    Qiao S; Luo JH; Jin JH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.